Total Payments
$12,998
2024 Payments
$1,644
Companies
35
Transactions
601
Medicare Patients
15,281
Medicare Billing
$3.5M
Payment Breakdown by Category
Food & Beverage$12,921 (99.4%)
Education$76.96 (0.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,921 | 591 | 99.4% |
| Education | $76.96 | 10 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $1,995 | 81 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,716 | 94 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,463 | 84 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,398 | 68 | $0 (2024) |
| Abbott Laboratories | $855.96 | 21 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $763.88 | 32 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $668.73 | 29 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $633.47 | 36 | $0 (2024) |
| PFIZER INC. | $467.68 | 27 | $0 (2024) |
| Amarin Pharma Inc. | $376.94 | 17 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,644 | 81 | E.R. Squibb & Sons, L.L.C. ($313.03) |
| 2023 | $1,562 | 76 | Novartis Pharmaceuticals Corporation ($455.53) |
| 2022 | $1,304 | 60 | Novartis Pharmaceuticals Corporation ($310.69) |
| 2021 | $2,351 | 94 | Janssen Pharmaceuticals, Inc ($419.11) |
| 2020 | $1,234 | 56 | Amgen Inc. ($301.25) |
| 2019 | $1,645 | 78 | Amgen Inc. ($336.97) |
| 2018 | $1,521 | 75 | Amgen Inc. ($480.74) |
| 2017 | $1,738 | 81 | Amgen Inc. ($329.91) |
All Payment Transactions
601 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $8.60 | General |
| Category: Cardiac Rhythm Management | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/06/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Cardiac Rhythm Management | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $31.45 | General |
| Category: Cardiovascular | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $3.13 | General |
| Category: Cardiovascular | ||||||
| 11/21/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $31.66 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $29.68 | General |
| Category: Cardiovascular | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: Cardio-renal | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $6.34 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $0.45 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/01/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $10.89 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/31/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $12.38 | General |
| Category: Cardiovascular | ||||||
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $2.31 | General |
| Category: Cardiovascular | ||||||
| 10/30/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $0.74 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/23/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $34.79 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/22/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| Category: Cardiovascular | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.13 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/11/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $20.41 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/17/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $8.77 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/04/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $26.45 | General |
| Category: Cardiovascular | ||||||
| 09/03/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $4.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: Cardio-renal | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 3,800 | 4,982 | $2.9M | $868,502 |
| 2022 | 24 | 3,931 | 5,107 | $3.0M | $892,292 |
| 2021 | 25 | 4,161 | 5,479 | $3.1M | $942,259 |
| 2020 | 22 | 3,389 | 4,501 | $2.7M | $780,217 |
Total Patients
15,281
Total Services
20,069
Medicare Billing
$3.5M
Procedure Codes
100
All Medicare Procedures & Services
100 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2023 | 159 | 160 | $960,000 | $203,506 | 21.2% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 160 | 322 | $644,000 | $131,331 | 20.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 551 | 1,137 | $170,625 | $117,902 | 69.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 336 | 483 | $109,025 | $71,759 | 65.8% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 80 | 85 | $110,500 | $66,893 | 60.5% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 263 | 266 | $166,250 | $55,511 | 33.4% |
| 33285 | Insertion of heart rhythm monitor under skin | Office | 2023 | 12 | 12 | $96,000 | $48,986 | 51.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 252 | 274 | $163,565 | $44,892 | 27.4% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 167 | 168 | $67,200 | $28,691 | 42.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 88 | 88 | $35,200 | $15,389 | 43.7% |
| 93978 | Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | Office | 2023 | 97 | 98 | $34,300 | $13,002 | 37.9% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Office | 2023 | 250 | 252 | $40,320 | $11,562 | 28.7% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 158 | 159 | $51,675 | $9,992 | 19.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 99 | $12,870 | $9,869 | 76.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 43 | 50 | $20,000 | $7,265 | 36.3% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 160 | 161 | $32,200 | $7,061 | 21.9% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Office | 2023 | 250 | 252 | $40,320 | $5,489 | 13.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 371 | 415 | $37,350 | $5,204 | 13.9% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 29 | 49 | $4,900 | $3,375 | 68.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 48 | 57 | $20,520 | $3,270 | 15.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 33 | $4,125 | $2,188 | 53.0% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 14 | 92 | $9,200 | $2,007 | 21.8% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 78 | 83 | $41,500 | $1,729 | 4.2% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 15 | 15 | $7,500 | $907.59 | 12.1% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 11 | 11 | $1,760 | $642.58 | 36.5% |
About Dr. George Grifka, M.D
Dr. George Grifka, M.D is a Cardiovascular Disease healthcare provider based in Santa Monica, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1326189580.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. George Grifka, M.D has received a total of $12,998 in payments from pharmaceutical and medical device companies, with $1,644 received in 2024. These payments were reported across 601 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($12,921).
As a Medicare-enrolled provider, Grifka has provided services to 15,281 Medicare beneficiaries, totaling 20,069 services with total Medicare billing of $3.5M. Data is available for 4 years (2020–2023), covering 100 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Santa Monica, CA
- Active Since 02/09/2007
- Last Updated 03/27/2008
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1326189580
Products in Payments
- ELIQUIS (Drug) $1,614
- XARELTO (Drug) $1,398
- Repatha (Biological) $1,395
- ENTRESTO (Drug) $893.26
- LEQVIO (Drug) $822.38
- Corlanor (Drug) $599.90
- MULTAQ (Drug) $443.35
- Confirm Rx (Device) $396.23
- Vascepa (Drug) $376.94
- PRADAXA (Drug) $372.95
- JARDIANCE (Drug) $366.53
- BRILINTA (Drug) $333.75
- NEXLETOL (Drug) $315.85
- VERQUVO (Drug) $300.76
- FARXIGA (Drug) $299.72
- CAMZYOS (Drug) $227.86
- PRALUENT (Drug) $225.38
- Reveal LINQ (Device) $218.01
- CONFIRM RX (Device) $195.51
- Edarbi (Drug) $193.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Santa Monica
Shephal Doshi, M.d, M.D
Cardiovascular Disease — Payments: $2.0M
Cardiovascular Disease $2.0M
Richard Wright, M.d, M.D
Cardiovascular Disease — Payments: $1.8M
Cardiovascular Disease $1.8M
Vikram Rajan, M.d, M.D
Cardiovascular Disease — Payments: $37,005
Cardiovascular Disease $37,005
Peter Pelikan, M.d, M.D
Cardiovascular Disease — Payments: $18,000
Cardiovascular Disease $18,000
Alexandra Lajoie, M.d, M.D
Cardiovascular Disease — Payments: $9,422
Cardiovascular Disease $9,422
Dr. Christiane Schaeffler, M.d, M.D
Cardiovascular Disease — Payments: $6,604
Cardiovascular Disease $6,604